COMPASS Pathways reports Q2 net loss of $21.0M, appoints Kabir Nath as CEO

COMPASS Pathways plc

2022-Q2 EPS reported -$1.00

Net loss for Q2 2022 was $21.0M ($0.50 loss per share) vs $17.5M ($0.44) in Q2 2021.
Cash and cash equivalents of $207.2M at June 30, 2022, down from $273.2M at Dec 31, 2021.
Kabir Nath appointed CEO; George Goldsmith remains Executive Chairman through Dec 2022.
Phase 3 protocols for COMP360 in TRD submitted to FDA, under review; Phase 3 start expected Q4 2022.
Phase 2 study of COMP360 in anorexia nervosa launched across four research sites in the UK and US.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.